Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frances R Balkwill

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
The Journal of Pathology|October 13, 2011
The chemokine system and cancerFrances R Balkwill
Seminars in Cancer Biology|January 3, 2012
Cancer-related inflammation: common themes and therapeutic opportunitiesFrances R Balkwill, Alberto Mantovani
Immunity|November 22, 2018
Mets and NETs: The Awakening ForceVictoria Sanz-Moreno, Frances R Balkwill
Nature Reviews. Clinical Oncology|January 8, 2022
Harnessing cytokines and chemokines for cancer therapyDavid J Propper, Frances R Balkwill
Nature Reviews. Clinical Oncology|July 1, 2015
Inflammation and cancer: advances and new agentsShanthini M Crusz, Frances R Balkwill
The Lancet. Oncology|September 11, 2003
Tumour necrosis factor alpha: a potential target for the therapy of solid tumoursPeter W Szlosarek, Frances R Balkwill
European Journal of Cancer (Oxford, England : 1990)|March 7, 2006
Tumour necrosis factor-alpha as a tumour promoterPeter Szlosarek, Kellie A Charles, Frances R Balkwill
Molecular Cancer Therapeutics|January 9, 2003
Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cellsMatthew J Grimshaw, Stuart Naylor, Frances R Balkwill
European Journal of Immunology|January 29, 2002
Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alphaStephen C Robinson, Kate A Scott, Frances R Balkwill
European Journal of Immunology|September 11, 2002
Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumorsMatthew J Grimshaw, Julia L Wilson, Frances R Balkwill
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
The Journal of Pathology|October 13, 2011
The chemokine system and cancerFrances R Balkwill
Seminars in Cancer Biology|January 3, 2012
Cancer-related inflammation: common themes and therapeutic opportunitiesFrances R Balkwill, Alberto Mantovani
Immunity|November 22, 2018
Mets and NETs: The Awakening ForceVictoria Sanz-Moreno, Frances R Balkwill
Nature Reviews. Clinical Oncology|January 8, 2022
Harnessing cytokines and chemokines for cancer therapyDavid J Propper, Frances R Balkwill
Nature Reviews. Clinical Oncology|July 1, 2015
Inflammation and cancer: advances and new agentsShanthini M Crusz, Frances R Balkwill
The Lancet. Oncology|September 11, 2003
Tumour necrosis factor alpha: a potential target for the therapy of solid tumoursPeter W Szlosarek, Frances R Balkwill
European Journal of Cancer (Oxford, England : 1990)|March 7, 2006
Tumour necrosis factor-alpha as a tumour promoterPeter Szlosarek, Kellie A Charles, Frances R Balkwill
Molecular Cancer Therapeutics|January 9, 2003
Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cellsMatthew J Grimshaw, Stuart Naylor, Frances R Balkwill
European Journal of Immunology|January 29, 2002
Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alphaStephen C Robinson, Kate A Scott, Frances R Balkwill
European Journal of Immunology|September 11, 2002
Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumorsMatthew J Grimshaw, Julia L Wilson, Frances R Balkwill
Pageof 8